$4.69B Verdict Against J&J in St. Louis Talc Case
July 2018 verdict awarded 22 women $4.69 billion for ovarian cancer linked to J&J baby powder, the largest talc verdict in history at the time.
Landmark Verdict Rocks Johnson & Johnson
On July 12, 2018, a St. Louis jury awarded $4.69 billion to 22 women who claimed Johnson & Johnson’s talc-based baby powder caused their ovarian cancer. The verdict was the largest talc-related jury award in history.
The award included $550 million in compensatory damages ($25 million per plaintiff) and $4.14 billion in punitive damages, signaling the jury’s belief that J&J had acted with reckless disregard for consumer safety.
The Plaintiffs’ Case
The 22 women, from 12 different states, alleged that decades of using J&J’s baby powder and Shower to Shower products caused them to develop ovarian cancer. Their attorneys presented:
Internal documents showing:
- J&J knew about potential asbestos contamination in talc supplies
- Company tested talc products and found asbestos fibers
- Executives discussed contamination concerns but continued sales
- Marketing specifically targeted women for genital hygiene use
Scientific evidence linking:
- Talc particles migrating through the reproductive tract to ovaries
- Chronic inflammation leading to cancer development
- Asbestos contamination in talc increasing cancer risk
Johnson & Johnson’s Defense
J&J maintained throughout the trial that:
- Their talc products were safe and asbestos-free
- Decades of testing confirmed product safety
- Scientific evidence did not support a causal link to ovarian cancer
- The plaintiffs’ experts relied on flawed studies
The company announced it would appeal the verdict, calling it “fundamentally unfair” due to the consolidation of 22 plaintiffs in a single trial.
Verdict Breakdown
| Category | Amount |
|---|---|
| Compensatory damages (22 plaintiffs) | $550 million |
| Punitive damages | $4.14 billion |
| Total verdict | $4.69 billion |
The punitive damages reflected the jury’s finding that J&J’s conduct warranted punishment beyond compensation for actual injuries.
The St. Louis verdict demonstrated juries would hold companies accountable for concealment. It established that massive punitive damages were possible and contributed to J&J’s eventual discontinuation of talc baby powder and over 90,000 lawsuits by 2025.
Aftermath and Appeals
Appeal outcome:
- Missouri Court of Appeals reduced the verdict to approximately $2.12 billion in June 2020
- Court dismissed claims of most non-resident plaintiffs for lack of personal jurisdiction under Bristol-Myers Squibb v. Superior Court
- Liability for the remaining plaintiffs was affirmed, and the Missouri Supreme Court denied further review in 2021
Broader impact:
- Sent “shockwaves across the world” according to legal observers
- Encouraged thousands more plaintiffs to file claims
- Contributed to J&J’s decision to discontinue talc baby powder
- Led to increased scrutiny of talc in cosmetics
The Talc-Ovarian Cancer Connection
Research presented at trial showed:
- Women who used talc products for genital hygiene had increased ovarian cancer risk
- Talc particles have been found in ovarian tumors
- Some talc supplies were contaminated with asbestos from shared geological deposits
- IARC later classified talc as “probably carcinogenic” (Group 2A) in 2024
Context: Growing Litigation
The St. Louis verdict came amid a wave of talc lawsuits:
| Year | Development |
|---|---|
| 2016 | First major talc verdicts (ovarian cancer) |
| 2017 | Multiple verdicts against J&J |
| 2018 | $4.69 billion St. Louis verdict |
| 2018 | Reuters investigation reveals internal documents |
| 2019 | FDA finds asbestos in J&J baby powder |
| 2020 | J&J halts North American talc sales |
| 2023 | Global talc baby powder discontinuation |
What This Meant for Consumers
The verdict highlighted several concerns:
For those who used talc products:
- Document usage history
- Monitor for symptoms
- Consult healthcare providers about cancer screening
- Understand legal options if diagnosed
For the industry:
- Increased pressure to reformulate products
- Greater scrutiny of talc sourcing and testing
- Consumer shift toward talc-free alternatives
Long-Term Significance
The St. Louis verdict was a turning point in talc litigation:
- Demonstrated juries would hold companies accountable for concealment
- Established that massive punitive damages were possible
- Contributed to eventual IARC reclassification of talc
- Paved the way for mesothelioma-specific talc lawsuits
By 2025, J&J faced over 90,000 talc-related lawsuits and had attempted multiple bankruptcy strategies to resolve claims, a direct consequence of verdicts like the 2018 St. Louis case.
Reader Q&A
Frequently Asked Questions
What was the St. Louis talc verdict?
In July 2018, a St. Louis jury awarded $4.69 billion to 22 women who claimed J&J’s talc baby powder caused their ovarian cancer. It was the largest talc verdict in history, including $550 million in compensatory damages and $4.14 billion in punitive damages.
What happened on appeal?
The Missouri Court of Appeals reduced the verdict to about $2.12 billion in June 2020. The court dismissed claims brought by most non-resident plaintiffs for lack of personal jurisdiction under Bristol-Myers Squibb v. Superior Court but affirmed liability for the remaining plaintiffs. The Missouri Supreme Court denied further review in 2021.
What evidence did plaintiffs present?
Internal documents showing J&J knew about potential asbestos contamination, tested products and found asbestos fibers, discussed contamination concerns but continued sales, and specifically marketed talc to women for genital hygiene use.
What was the broader impact?
The verdict sent “shockwaves” through the industry, encouraged thousands more plaintiffs, contributed to J&J discontinuing talc baby powder, increased cosmetic talc scrutiny, and led to IARC classifying talc as “probably carcinogenic” in 2024.
How much is the talcum powder lawsuit going to payout?
Talcum powder lawsuits linked to mesothelioma in people with exposure to asbestos-contaminated products have resulted in varied payouts, with averages for mesothelioma claims reported between $1 million and $1.4 million according to Mealey’s Asbestos Litigation Report. Legal industry estimates place general talc settlements lower, around $500,000 per plaintiff, though individual verdicts range from $8 million to over $966 million before reductions. Johnson & Johnson has proposed multi-billion-dollar funds, such as $6.48 billion in 2024, but final per-person amounts depend on case details like diagnosis severity and usage duration, with many resolved confidentially.
What is talc litigation?
Talc litigation involves lawsuits filed by people with ovarian cancer or mesothelioma who allege that asbestos-contaminated talc-based products, such as Johnson & Johnson Baby Powder, caused their illnesses due to manufacturers’ failure to warn of known risks. As of May 2026, over 63,000 families pursue claims against Johnson & Johnson and talc suppliers, with juries awarding billions in verdicts, including an $8 million mesothelioma award in 2023 and multi-billion dollar ovarian cancer cases. Evidence includes epidemiological studies linking talc particles or asbestos to ovarian inflammation and cancer, internal company documents from the 1970s, and 2025 federal court rejection of Johnson & Johnson’s third bankruptcy resolution attempt. Ongoing multidistrict litigation in New Jersey oversees thousands of cases, with settlement talks mediated but no global resolution reached. Peer-reviewed analyses note mixed trial outcomes reliant on recalled product use and contamination proof.
Has anyone received a settlement from Johnson & Johnson?
Yes, people with mesothelioma and ovarian cancer have received settlements from Johnson & Johnson for claims involving asbestos-contaminated talc products. Notable examples include a $700 million multistate settlement in 2024 for deceptive marketing practices and a $100 million settlement in 2020 resolving over 1,000 claims. Verdicts with settlements have ranged from $45 million in an Illinois mesothelioma case to $966 million in a California case, though global settlement proposals like J&J’s $9 billion offer were rejected as of 2025. Ongoing lawsuits number around 67,000 in New Jersey.
What is the average payout for Johnson & Johnson?
Johnson & Johnson talcum powder lawsuit settlements and verdicts show wide variation, with no fixed average payout across all claims. Legal industry estimates for talcum powder cases range from $100,000 to over $1 million per person, while mesothelioma-specific claims average $1 million to $1.4 million. Proposed settlements, such as the $8.9 billion offer in 2023 for thousands of claimants or $8.2 billion in 2024, project per-claimant payouts around $330,000 to $500,000 after division among plaintiffs. Individual verdicts include $1.5 million for a mesothelioma case in 2018 and $16 million compensatory damages upheld in 2026. Payouts depend on case details like injury type and asbestos exposure evidence.